Invest in the future of uterine therapeutics
Why Meliodays?
Unmet need
Dysmenorrhea, or period pain, affects up to 85% of women globally, with 25% reporting pain so severe it disrupts daily life. Despite this scale, treatment options remain limited or inadequate.
Category-creating innovation
MelioOne® is being developed as the first non-contraceptive, non-hormonal intrauterine device designed to support relief in period pain. By combining an established class of pain medication (NSAIDs) with a local delivery format, Meliodays is pioneering a new category: local uterine therapeutics.
Early validation
We have completed large-scale consumer research with 800+ women in Germany and the US, confirming high unmet need and willingness to adopt alternatives to systemic or hormonal treatments. Pre-clinical development is underway, supported by partners including Celanese and BioLegacy.
Pathway & scalability
As a combination product, device + pharmacological agent, MelioOne® follows the rigorous regulatory pathway typical of pharmaceutical innovation. Our target launch is 2029, subject to clinical and regulatory milestones. The IUD platform offers scalability across further uterine indications beyond menstruation.
Professional Investors
We are developing a first-in-class therapeutic device in the €96B global femtech market projected for 2030 — a sector that remains largely underserved. To support the regulatory development of MelioOne®, we plan to raise funding in regular rounds on an annual basis.
Professional investors can request a pitch document below or email us at ir@meliodays.com.
Impact Investors
For those driven by measurable social return, Meliodays offers a rare opportunity: closing the gender health gap through evidence-based innovation. By supporting our work, impact investors can align capital with systemic change to improve equity, education, and women’s quality of life.
Participate via Capacura with investments starting from €1,000 through the link below.
Our Progress So Far
-
Q1 2024
Global IP priority secured.
Patent number: WO2024170690A1 -
Q3 2024
Prototype development with Celanese on polymer + API formulation kick-started
-
Q1 2025
€800K Pre-seed round closure led by Capacura, FS Investment, OHA and Heimat Boost
Large-scale survey with 800 women conducted in the US and Germany with Dynata
-
Q3 2025
National IP secured in key markets: US, EU, China and Japan
Nonclinical development kick-started with Premier Research, Technical University Munich and BioLegacy Research